中国普通外科杂志2024，Vol.33Issue(1)：1-8,8.DOI:10.7659/j.issn.1005-6947.2024.01.001
《靶向免疫联合局部治疗中晚期肝细胞癌中国专家共识》解读
Interpretation of the Chinese expert consensus on targeted-immune combination local therapy for advanced hepatocellular carcinoma
摘要
Abstract
China is a high-incidence country for hepatocellular carcinoma(HCC),with consistently high rates of both morbidity and mortality.The majority of HCC patients are already in the advanced stages at the time of diagnosis,losing the opportunity for surgery.Combined targeted therapy and immunotherapy(targeted-immune combination)and targeted-immune combination local therapy have become the hot topic in the treatment of advanced-stage HCC in recent years.Combination therapy based on immune checkpoint inhibitors has significantly improved the efficacy for patients with advanced-stage HCC.However,there is a significant difference in treatment plans and experiences among different medical institutions,lacking a unified consensus and a model for comprehensive management as a reference.Recently,the Hepatic Oncology Branch and Immunology Branch of China International Exchange and Promotive Association for Medical and Health Care and the Expert Consensus Collaborative Group on Targeted-Immune Combination Local Therapy for Advanced Hepatocellular Carcinoma took the lead in formulating and releasing the Chinese expert consensus on targeted-immune combination local therapy for advanced hepatocellular carcinoma.This consensus provides detailed explanations from various perspectives on the definition of targeted-immune combination local therapy for HCC,the eligible population and management,the selection of treatment methods,strategies for converting unresectable tumors into resectable tumors,treatment strategies for tumor progression,and the management of common adverse reactions.Here,the authors interpret the key points of this consensus and look ahead to how the consensus can adapt to the current background of research or practice.关键词
癌,肝细胞/分子靶向治疗/免疫疗法/共识Key words
Carcinoma,Hepatocellular/Molecular Targeted Therapy/Immunotherapy/Consensus分类
医药卫生引用本文复制引用
朱成佩,赵海涛..《靶向免疫联合局部治疗中晚期肝细胞癌中国专家共识》解读[J].中国普通外科杂志,2024,33(1):1-8,8.基金项目
北京协和医院中央高水平医院临床科研专项基金资助项目(2022-PUMCH-B-128) （2022-PUMCH-B-128）
中国医学科学院临床与转化医学研究专项滚动基金资助项目(2022-I2M-C&T-A-003) （2022-I2M-C&T-A-003）
中国医学科学院医学与健康科技创新工程基金资助项目(2021-I2M-1-061) （2021-I2M-1-061）
希思科-默沙东肿瘤研究基金资助项目(Y-MSDZD2021-0213) （Y-MSDZD2021-0213）
希思科-恒瑞肿瘤研究基金项目(Y-HR2019-0239) （Y-HR2019-0239）
国家高层次人才特殊支持计划(万人计划)基金资助项目. （万人计划）
